“Our results demonstrated the superiority of the (Microfluidic Aerosolization Platform) over the conventional vibrating mesh nebulizer, as it avoided problems such as particle aggregation, loss of mRNA encapsulation, and deformation of the nanoparticle morphology.” “This may represent an advancement for the pulmonary gene therapy, enabling precise and effective delivery of aerolized nanoparticles.
- Kim et al, 2024
Review the promise of Rare Air's Microfluidic Aerosolization Platform™ in this peer reviewed ACS Nano Publication
The World’s First Digitally Native, Precision Pulmonary Drug Delivery Platform
Rare Air Health's proprietary Microfluidic Aerosolization Platform™ (MAP) brings aerosolized gene therapy to the world in the easiest way. MAP eliminates the need for injections with our state-of-the-art pulmonary drug delivery system. By directly targeting the pulmonary system, MAP increases the speed and efficacy of pulmonary gene therapies.WHY RARE AIR
Direct pulmonary delivery allows a rapid and targeted local response to respiratory and chronic pulmonary diseases which primarily target the airways and lungs. Against respiratory diseases such as SARS-CoV2, activation of the mucosal immunity along the pulmonary pathway is key.
MORE EFFECTIVE
Direct localized delivery increases treatment efficacy at lower dosage compared to systemic routes such as injectables. This reduces treatment costs and the impacts of systemic adverse effects such as drug toxicity.
LOCALIZED TREATMENT
Digital native solutions allow seamless integration of information directly into healthcare information systems. HIPPA-compliant epidemiological data can be accessed for research and public health purposes.
DIGITALLY NATIVE
Eliminating injections allows patients a more convenient and comfortable way to access leading edge therapies. This improves access and treatment compliance, especially among children and the needle-apprehensive population.
EASE OF USE
Rare Air’s pulmonary delivery technology can be rapidly deployed in existing and new facilities with significant cost savings by eliminating the specialized staffing and administrative resources required for injectables.
SCALABLE
MAP technology is self-propelling and does not utilize propellants such as hydrofluorocarbon (HFC) for aerosolization. Its component parts and consumables are also recyclable, resulting in less landfill waste.
SUSTAINABLE